vs
ADAMAS TRUST, INC.（ADAM）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是ADAMAS TRUST, INC.的1.6倍（$69.8M vs $43.2M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 124.0%，领先260.0%），ADAMAS TRUST, INC.同比增速更快（61.6% vs 21.2%），过去两年ADAMAS TRUST, INC.的营收复合增速更高（55.5% vs 53.7%）
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ADAM vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.6倍
$43.2M
营收增速更快
ADAM
高出40.4%
21.2%
净利率更高
RIGL
高出260.0%
124.0%
两年增速更快
ADAM
近两年复合增速
53.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.2M | $69.8M |
| 净利润 | $53.5M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 124.0% | 384.0% |
| 营收同比 | 61.6% | 21.2% |
| 净利润同比 | 270.5% | 1769.2% |
| 每股收益（稀释后） | $0.45 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADAMRIGL
| Q4 25 | $43.2M | $69.8M | ||
| Q3 25 | $36.6M | $69.5M | ||
| Q2 25 | $36.4M | $101.7M | ||
| Q1 25 | $33.1M | $53.3M | ||
| Q4 24 | $26.7M | $57.6M | ||
| Q3 24 | $20.2M | $55.3M | ||
| Q2 24 | $19.0M | $36.8M | ||
| Q1 24 | $17.9M | $29.5M |
净利润ADAMRIGL
| Q4 25 | $53.5M | $268.1M | ||
| Q3 25 | $44.8M | $27.9M | ||
| Q2 25 | $8.5M | $59.6M | ||
| Q1 25 | $42.2M | $11.4M | ||
| Q4 24 | $-31.4M | $14.3M | ||
| Q3 24 | $42.8M | $12.4M | ||
| Q2 24 | $-15.6M | $-1.0M | ||
| Q1 24 | $-57.9M | $-8.2M |
毛利率ADAMRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率ADAMRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | — | 40.9% | ||
| Q2 25 | 11.7% | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | -119.0% | 28.9% | ||
| Q3 24 | — | 25.4% | ||
| Q2 24 | -124.7% | 1.2% | ||
| Q1 24 | -448.8% | -23.6% |
净利率ADAMRIGL
| Q4 25 | 124.0% | 384.0% | ||
| Q3 25 | 122.5% | 40.2% | ||
| Q2 25 | 23.4% | 58.6% | ||
| Q1 25 | 127.4% | 21.5% | ||
| Q4 24 | -117.5% | 24.9% | ||
| Q3 24 | 211.7% | 22.5% | ||
| Q2 24 | -81.9% | -2.8% | ||
| Q1 24 | -324.1% | -27.9% |
每股收益（稀释后）ADAMRIGL
| Q4 25 | $0.45 | $14.11 | ||
| Q3 25 | $0.36 | $1.46 | ||
| Q2 25 | $-0.04 | $3.28 | ||
| Q1 25 | $0.33 | $0.63 | ||
| Q4 24 | $-0.46 | $0.82 | ||
| Q3 24 | $0.36 | $0.70 | ||
| Q2 24 | $-0.29 | $-0.06 | ||
| Q1 24 | $-0.75 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $210.3M | $155.0M |
| 总债务越低越好 | $735.8M | $52.5M |
| 股东权益账面价值 | $1.4B | $391.5M |
| 总资产 | $12.6B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.52× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ADAMRIGL
| Q4 25 | $210.3M | $155.0M | ||
| Q3 25 | $185.3M | $137.1M | ||
| Q2 25 | $160.4M | $108.4M | ||
| Q1 25 | $177.1M | $77.1M | ||
| Q4 24 | $167.4M | $77.3M | ||
| Q3 24 | $195.1M | $61.1M | ||
| Q2 24 | $235.5M | $49.1M | ||
| Q1 24 | $226.9M | $49.5M |
总债务ADAMRIGL
| Q4 25 | $735.8M | $52.5M | ||
| Q3 25 | $766.6M | $60.0M | ||
| Q2 25 | $653.0M | $60.0M | ||
| Q1 25 | $654.4M | $60.0M | ||
| Q4 24 | $573.2M | $60.0M | ||
| Q3 24 | $699.4M | $60.0M | ||
| Q2 24 | $800.7M | $60.0M | ||
| Q1 24 | $1.0B | $60.0M |
股东权益ADAMRIGL
| Q4 25 | $1.4B | $391.5M | ||
| Q3 25 | $1.4B | $117.6M | ||
| Q2 25 | $1.4B | $81.9M | ||
| Q1 25 | $1.4B | $18.6M | ||
| Q4 24 | $1.4B | $3.3M | ||
| Q3 24 | $1.4B | $-14.6M | ||
| Q2 24 | $1.4B | $-29.9M | ||
| Q1 24 | $1.5B | $-31.7M |
总资产ADAMRIGL
| Q4 25 | $12.6B | $513.6M | ||
| Q3 25 | $12.4B | $242.5M | ||
| Q2 25 | $10.6B | $206.7M | ||
| Q1 25 | $10.0B | $176.0M | ||
| Q4 24 | $9.2B | $164.0M | ||
| Q3 24 | $8.9B | $139.4M | ||
| Q2 24 | $8.2B | $128.4M | ||
| Q1 24 | $7.4B | $126.5M |
负债/权益比ADAMRIGL
| Q4 25 | 0.52× | 0.13× | ||
| Q3 25 | 0.55× | 0.51× | ||
| Q2 25 | 0.47× | 0.73× | ||
| Q1 25 | 0.47× | 3.23× | ||
| Q4 24 | 0.41× | 18.25× | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.56× | — | ||
| Q1 24 | 0.67× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $125.9M | — |
| 自由现金流率自由现金流/营收 | 291.6% | — |
| 资本支出强度资本支出/营收 | 18.9% | — |
| 现金转化率经营现金流/净利润 | 2.50× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ADAMRIGL
| Q4 25 | $134.0M | $22.0M | ||
| Q3 25 | $6.9M | $24.0M | ||
| Q2 25 | $39.2M | $30.5M | ||
| Q1 25 | $25.8M | $-893.0K | ||
| Q4 24 | $14.1M | $14.5M | ||
| Q3 24 | $-922.0K | $21.7M | ||
| Q2 24 | $-993.0K | $302.0K | ||
| Q1 24 | $-13.1M | $-5.0M |
自由现金流ADAMRIGL
| Q4 25 | $125.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-10.6M | — | ||
| Q3 24 | $-8.6M | — | ||
| Q2 24 | $-8.6M | — | ||
| Q1 24 | $-19.1M | — |
自由现金流率ADAMRIGL
| Q4 25 | 291.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -39.6% | — | ||
| Q3 24 | -42.3% | — | ||
| Q2 24 | -44.9% | — | ||
| Q1 24 | -107.0% | — |
资本支出强度ADAMRIGL
| Q4 25 | 18.9% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 92.3% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 39.7% | — | ||
| Q1 24 | 33.5% | — |
现金转化率ADAMRIGL
| Q4 25 | 2.50× | 0.08× | ||
| Q3 25 | 0.15× | 0.86× | ||
| Q2 25 | 4.59× | 0.51× | ||
| Q1 25 | 0.61× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | -0.02× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
RIGL
暂无分部数据
